Intravenous thrombolysis before thrombectomy for acute ischaemic stroke
- PMID: 35810759
- DOI: 10.1016/S0140-6736(22)01286-7
Intravenous thrombolysis before thrombectomy for acute ischaemic stroke
Conflict of interest statement
I report a grant from Cerenovus (investigator-initiated ENDOLOW trial testing endovascular therapy for ischaemic stroke with a low National Institutes of Health Stroke Scale score); personal fees from Bayer (national leader of Bayer-PACIFIC trial testing Factor XIa inhibitor for stroke prevention), Lumosa (data safety monitoring board and scientific advisory board for development of novel thrombolytic), Basking Biosciences (scientific advisory board for development of novel thrombolytic), and Diamedica (scientific advisory board for development of novel cerebroprotective agent); royalties from UpToDate, all outside the area of work commented on here; and funds to my department from Genentech over 36 months ago for effort as lead principal investigator of the PRISMS trial, which tested alteplase for mild ischaemic stroke.
Comment on
-
Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label, blinded-outcome, randomised non-inferiority trial.Lancet. 2022 Jul 9;400(10346):104-115. doi: 10.1016/S0140-6736(22)00537-2. Lancet. 2022. PMID: 35810756 Clinical Trial.
-
Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial.Lancet. 2022 Jul 9;400(10346):116-125. doi: 10.1016/S0140-6736(22)00564-5. Lancet. 2022. PMID: 35810757 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical